Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Open accessThe DOI matches its Crossref record; 33 of the 36 references it cites were found in a registry or an index.
Abstract
Background Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU). It is unclear whether this occurs because such tumours have better prognosis or they are more sensitive to 5-FU treatment.Patients and methods Associations between TS, DPD and TP levels, determined by tissue microarrays and immunohistochemistry, and survival was evaluated in 945 CRC patients according to treatment status.Results Low TS and DPD expression associated with worse prognosis in stage II [hazard ratio (HR) = 1.69, 95% confidence interval (CI) (1.09-2.63) and HR = 1.92 (95% CI 1.23-2.94), respectively] and stage III CRC patients treated by surgery alone [HR = 1.39 (95% CI 0.92-2.13) and HR = 1.49 (95% CI 1.02-2.17), respectively]. Low TS, DPD and TP associated with trends for better outcome in stage III patients treated with 5-FU [HR = 0.81 (95% CI 0.49-1.33), HR = 0.70 (95% CI 0.42-1.15) and HR = 0.66 (95% CI 0.39-1.12), respectively].Conclusion Low TS and DPD expression are prognostic for worse outcome in CRC patients treated by surgery alone, whereas low TS, DPD and TP expression are prognostic for better outcome in patients treated with 5-FU chemotherapy. These results provide indirect evidence that low TS, DPD and TP protein expression are predictive of good response to 5-FU chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As the name implies, high expression of DPD mRNA can confer resistance to 5-FU in CRC [9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [10]
In the citing paper
“Studies have shown that the higher expression of TP predicts a good response to 5-FU [9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [10]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [10]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [10]
Citations
Cites
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-5-199503010-00001 · Cited by 925
Salonga, D. S., Danenberg, K. D., Johnson, M. R., Metzger, R., Groshen, S. G., Tsao-Wei, D. D., Lenz, H.-J., Leichman, C. G., Leichman, L., Diasio, R. B., et al. (2000) · PubMed · Cited by 829
Self-citationClinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials
Sargent, D. J., Conley, B. A., Allegra, C., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.112 · Cited by 499
Popat, S., Matakidou, A., & Houlston, R. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.064 · Cited by 449
Beck, A., Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Renée, N., & Milano, G. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00216-r · Cited by 270
Edler, D., Glimelius, B. L. G., Hallström, M., Jakobsen, A. K. M., Johnston, P. G., Magnusson, I., Ragnhammar, P., & Blomgren, H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.039 · Cited by 263
Metzger, R., Danenberg, K. D., Leichman, C. G., Salonga, D. S., Schwartz, E. L., Wadler, S., Lenz, H., Groshen, S. G., Leichman, L., & Danenberg, P. V. (1998) · PubMed · Cited by 259
Elsaleh, H., Powell, B. L., McCaul, K. A., Grieu, F., Grant, R., Joseph, D., & Iacopetta, B. J. (2001) · PubMed · Cited by 204
Self-citation
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
Tejpar, S., Bertagnolli, M., Bosman, F., Lenz, H.-J., Garraway, L., Waldman, F., Warren, R., Bild, A., Collins-Brennan, D., Hahn, H., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0233 · Cited by 185
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Crea, F., Nobili, S., Paolicchi, E., Perrone, G., Napoli, C., Landini, I., Danesi, R., & Mini, E. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.08.001 · Cited by 137
Costantino, E., Maddalena, F., Calise, S. J., Piscazzi, A., Tirino, V., Fersini, A., Ambrosi, A., Neri, V., Esposito, F., & Landriscina, M. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.018 · Cited by 152
Sun, J., Han, J., Ahn, J. S., Park, K., & Ahn, M. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182208ea8 · Cited by 132
Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years
Panczyk, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9775 · Cited by 122
FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy
Mohelníková-Duchoňová, B., Melichar, B., & Soucek, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i30.10316 · Cited by 116
Gusella, M., Frigo, A. C., Bolzonella, C., Marinelli, R., Barile, C., Bononi, A., Crepaldi, G., Menon, D., Stievano, L., Toso, S., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605052 · Cited by 107
Koopman, M., Venderbosch, S., van Tinteren, H., Ligtenberg, M. J. L., Nagtegaal, I. D., van Krieken, J. H., & Punt, C. J. A. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.017 · Cited by 101
Koopman, M., Venderbosch, S., Nagtegaal, I. D., van Krieken, J. H., & Punt, C. J. A. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.023 · Cited by 98
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
Bluth, M. H., & Li, J. (2011) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s18861 · Cited by 93
Cutsem, E. V., Dicato, M. A., Arber, N., Berlin, J. D., Cervantes, A. M. R., Ciardiello, F., de Gramont, A., Díaz‐Rubio, E., Ducreux, M. P., Geva, R., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq273 · Cited by 88
Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update
Xie, P., Mo, J., Liu, J., Li, X., Tan, L., Zhang, W., Zhou, H., & Liu, Z. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00529-1 · Cited by 85
Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer
Kumar, A., Singh, A. K., Singh, H., Thareja, S., & Kumar, P. (2022) · Medical Oncology · doi:10.1007/s12032-022-01864-z · Cited by 76
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 74
5-Fluorouracil Pharmacogenomics: Still Rocking after all these years?
Scartozzi, M., Maccaroni, E., Giampieri, R., Pistelli, M., Bittoni, A., Prete, M. D., Berardi, R., & Cascinu, S. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.167 · Cited by 73
Molecular predictive and prognostic markers in colon cancer
Winder, T., & Lenz, H. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.005 · Cited by 72
Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision
Donada, M., Bonin, S., Barbazza, R., Pettirosso, D., & Stanta, G. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-36 · Cited by 60
Systems Pharmacology Assessment of the 5-Fluorouracil Pathway
Muhale, F., Wetmore, B. A., Thomas, R. S., & McLeod, H. L. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.188 · Cited by 57
Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 56
Pharmacogenetics of Drugs Used in the Treatment of Cancers
Franczyk, B., Rysz, J., & Gluba-Brzózka, A. (2022) · Genes · doi:10.3390/genes13020311 · Cited by 51
Chua, W. M., Kho, P. S., Moore, M. M., Charles, K. A., & Clarke, S. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.07.012 · Cited by 53
Kostopoulos, I. S., Karavasilis, V., Karina, M., Bobos, M., Xiros, N., Pentheroudakis, G. E., Kafiri, G., Papakostas, P., Vrettou, E., & Fountzilas, G. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-339 · Cited by 50
Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine
Perotti, A., Locatelli, A., Sessa, C., Hess, D., Viganò, L., Capri, G., Maur, M., Cerny, T., Cresta, S., Rojo, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5867 · Cited by 46
Molecular Predictors of Response to Chemotherapy in Colorectal Cancer
Dienstmann, R., Vilar, E., & Tabernero, J. M. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212f844 · Cited by 43
Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma
Kunická, T., Procházka, P., Krus, I., Bendová, P., Protivova, M., Susova, S., Hlaváč, V., Liška, V., Novák, P., Schneiderová, M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2826-8 · Cited by 43
Malier, M., Court, M., Gharzeddine, K., Laverierre, M.-H., Marsili, S., Thomas, F., Decaens, T., Roth, G. S., & Millet, A. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1572 · Cited by 45
Brockmueller, A., Girisa, S., Kunnumakkara, A. B., & Shakibaei, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054988 · Cited by 43
Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer.
Karlberg, M., Öhrling, K., Edler, D., Hallström, M., Ullén, H., & Ragnhammar, P. (2010) · PubMed · Cited by 43
Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer
Mao, C., Zeng, X., Zhang, C., Yang, Y., Xiao, X., Luan, S., Zhang, Y., & Yuan, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.612451 · Cited by 42
Villin Expression Is Frequently Lost in Poorly Differentiated Colon Cancer
Arango, D., Al-Obaidi, S. J., Williams, D. S., Dopeso, H., Mazzolini, R., Corner, G. A., Byun, D., Carr, A. A., Murone, C., Tögel, L., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.01.006 · Cited by 42
Self-citationToxicogenomics and Cancer Susceptibility: Advances with Next-Generation Sequencing
Ning, B., Su, Z., Mei, N., Hong, H., Deng, H., Shi, L. M., Fuscoe, J. C., & Tolleson, W. H. (2014) · Journal of Environmental Science and Health Part C · doi:10.1080/10590501.2014.907460 · Cited by 40
Afzal, S., Gusella, M., Jensen, S. A., Vainer, B., Vogel, U. B., Andersen, J. T., Br⊘dbæk, K., Petersen, M. A., Jimenez‐Solem, E., Adleff, V., et al. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.83 · Cited by 38
Albadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 38
Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon
Erstad, D. J., Tumusiime, G., & Cusack, J. C. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4706-x · Cited by 37
Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer
Mattos‐Arruda, L. D., Dienstmann, R., & Tabernero, J. M. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.03.030 · Cited by 37
Biomarkers in colorectal cancer
Markman, B., Rodríguez-Freixinós, V., & Tabernero, J. M. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0502-z · Cited by 35
Sun, J., Ahn, J. S., Park, K., Han, J., & Ahn, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7579 · Cited by 34
Pharmacogenetics and biomarkers in colorectal cancer
Strimpakos, A. S., Syrigos, K. N., & Saif, M. W. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.8 · Cited by 32
Savva-Bordalo, J., Ramalho-Carvalho, J., Pinheiro, M., Costa, V. L., Rodrigues, Â., Dias, P. C., Veiga, I., Machado, M., Teixeira, M. R., Henrique, R., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-470 · Cited by 31
Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma
Tänzer, M., Liebl, M. C., & Quante, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.06.005 · Cited by 30
Jensen, N. F., Smith, D. H., Nygård, S. B., Rømer, M. U., Nielsen, K. V., & Brünner, N. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.640835 · Cited by 29
Che, J., Pan, L., Yang, X., Liu, Z., Huang, L. J., Wen, C., Lin, A., & Liu, H. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1436 · Cited by 29
Hayashi, R., Ishii, Y., Ochiai, H., Matsunaga, A., Endo, T., Hasegawa, H., & Kitagawa, Y. (2012) · Oncology Reports · doi:10.3892/or.2012.1935 · Cited by 28
Donada, M., Bonin, S., Nardon, E., Pellegrin, A. D., Decorti, G., & Stanta, G. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0872-1 · Cited by 26
Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes
Avolio, M., & Trusolino, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1531 · Cited by 26
Molecular Prognostic and Predictive Markers in Colorectal Cancer: Current Status
Lee, J. K., & Chan, A. T. (2011) · Current Colorectal Cancer Reports · doi:10.1007/s11888-011-0091-4 · Cited by 26
van der Zee, J. A., van Eijck, C. H. J., Hop, W. C. J., van Dekken, H., Dicheva, B. M., Seynhaeve, A. L. B., Koning, G. A., Eggermont, A. M. M., & ten Hagen, T. L. M. (2012) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2012.04.013 · Cited by 24
GENETICS/GENOMICS AND DRUG EFFECTS
Heller, F. (2013) · Acta Clinica Belgica · doi:10.2143/acb.3210 · Cited by 23
Stravopodis, D. J., Karkoulis, P. K., Konstantakou, E. G., Melachroinou, S., Thanasopoulou, A., Aravantinos, G., Margaritis, L. H., Anastasiadou, E., & Voutsinas, G. E. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0891-y · Cited by 23
Ren, S.-N., Zhang, Z.-Y., Guo, R.-J., Wang, D., Chen, F., Chen, X., & Fang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1911 · Cited by 22
Recent applications of chemosensitivity tests for colorectal cancer treatment
Yoon, Y. S., & Kim, J. C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16398 · Cited by 22
Zhang, Y.-H., Cui, S., Wan, S., Wu, S., & Qu, X. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0460-0 · Cited by 22
Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer
Batra, A., Rigo, R., Hannouf, M. B., & Cheung, W. Y. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.09.006 · Cited by 21
Hao, W., Luo, D., Jiang, Y., Wan, S., & Li, X. (2024) · Medicinal Research Reviews · doi:10.1002/med.22044 · Cited by 22
Pharmacogenomics and -genetics in colorectal cancer
Pohl, A., Lurje, G., Manegold, P. C., & Lenz, H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.10.002 · Cited by 21
Approaches to Biomarkers in Human Colorectal Cancer: Looking Back, to go Forward
Nibbe, R. K., & Chance, M. R. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.33 · Cited by 20
Matsunaga, A., Ishii, Y., Tsuruta, M., Okabayashi, K., Hasegawa, H., & Kitagawa, Y. (2014) · Oncology Letters · doi:10.3892/ol.2014.2580 · Cited by 20
Gnoni, A., Russo, A. D., Silvestris, N., Maiello, E., Vacca, A., Marech, I., Numico, G., Paradiso, A., Lorusso, V., & Azzariti, A. (2011) · Current Drug Metabolism · doi:10.2174/138920011798062300 · Cited by 20
Grimminger, P., Schneider, P. M., Metzger, R., Vallböhmer, D., Hölscher, A. H., Danenberg, P. V., & Brabender, J. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.041 · Cited by 19
Petrioli, R., Bargagli, G., Lazzi, S., Pascucci, A., Francini, E., Bellan, C., Conca, R., Martellucci, I., Fiaschi, A. I., Lorenzi, B., et al. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328334d88a · Cited by 19
Personalized Medicine for Pancreatic Cancer: A Step in the Right Direction
Ko, A. H., & Tempero, M. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.11.027 · Cited by 19
Luo, D., Zhang, Y., Yang, S. C., Tian, X., Lv, Y., Guo, Z., Liu, X., Han, G., Liu, S., Wang, W., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113775 · Cited by 18
Shigeta, K., Ishii, Y., Hasegawa, H., Okabayashi, K., & Kitagawa, Y. (2014) · World Journal of Surgery · doi:10.1007/s00268-014-2738-1 · Cited by 18
Li, J., Sun, P., Huang, T., He, S., Li, L., & Xue, G. (2020) · Oncology Letters · doi:10.3892/ol.2020.12282 · Cited by 17
Lai, C.-Y., Hsieh, L.-L., Sung, F.-C., Tang, R., Bai, C., Wu, F.-Y., Chiou, H., & Yeh, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069039 · Cited by 16
Kim, N., & Yang, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031572 · Cited by 15
Sulżyc‐Bielicka, V., Domagała, P., Bielicki, D., Safranow, K., & Domagała, W. (2013) · Cellular Oncology · doi:10.1007/s13402-013-0159-z · Cited by 15
Shimamoto, Y., Nukatsuka, M., Takechi, T., & Fukushima, M. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2427 · Cited by 15
Yokoyama, Y., Sakatani, T., Wada, R., Ishino, K., Kudo, M., Koizumi, M., Yamada, T., Yoshida, H., & Naito, Z. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4895 · Cited by 15
Wang, Y., Wei, Q., Chen, Y., Long, S., Yao, Y., & Fu, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.604315 · Cited by 14
Sulżyc‐Bielicka, V., Domagała, P., Bielicki, D., Safranow, K., Rogowski, W., & Domagała, W. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0043-z · Cited by 14
Gajjar, K. K., Vora, H. H., Kobawala, T. P., Trivedi, T. I., & Ghosh, N. (2018) · The International Journal of Biological Markers · doi:10.1177/1724600817748539 · Cited by 14
Biomarkers in Colorectal Cancer
Lim, H. Y., & Toh, H. C. (2011) · Proceedings of Singapore Healthcare · doi:10.1177/201010581102000105 · Cited by 13
BET inhibitor bromosporine enhances 5-FU effect in colorectal cancer cells
Cheng, X., Huang, Z., Long, D., & Jin, W. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.009 · Cited by 13
Tsyganov, M. M., Ibragimova, M. K., Garbukov, Е. Y., Tsydenova, I. A., Gaptulbarova, K. A., Dolgasheva, D. S., Kravtsova, E. A., Frolova, A. A., Slonimskaya, E. M., & Литвяков, Н. В. (2022) · Diagnostics · doi:10.3390/diagnostics12020405 · Cited by 12
Merloni, F., Ranallo, N., Scortichini, L., Giampieri, R., & Berardi, R. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.006 · Cited by 12
Lai, C.-Y., Sung, F.-C., Hsieh, L.-L., Tang, R., Chiou, H., Wu, F.-Y., & Yeh, C. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3069-4 · Cited by 12
Saif, M. W., Hashmi, S., Bell, D., & Diasio, R. B. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903173217 · Cited by 12
Self-citationTanaka, K., Saigusa, S., Toiyama, Y., Koike, Y., Okugawa, Y., Yokoe, T., Inoue, Y., Kobayashi, M., Miki, C., & Kusunoki, M. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22123 · Cited by 11
Ma, Y., Lin, Y., Zou, B., Liu, W., Zhang, Y., Zhao, L., Huang, Y., Yang, Y., Fang, W., Zhao, Y., et al. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0395-2 · Cited by 11
Chen, Y., Yi, C., Liu, L., Li, B., Wang, Y., & Wang, X. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.9584 · Cited by 11
Clinical Management of Localized Colon Cancer with Capecitabine
Quidde, J., Arnold, D., & Stein, A. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s8194 · Cited by 11
Thymidine Phosphorylase Gene Expression in Stage III Colorectal Cancer
Lindskog, E. B., Wettergren, Y., Odin, E., Gustavsson, B. G., & Derwinger, K. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s10226 · Cited by 10
Zhao, Y., Zhao, Guo, Huang, Lin, Xue, Xu, Zhang, Zhao, Hu, et al. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s46498 · Cited by 9
What can the molecular pathologist offer for optimal decision making?
Richman, S. D., Hutchins, G. G. A., Seymour, M., & Quirke, P. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq379 · Cited by 10
Molecular and Clinical Oncology
Vahedi, A., Fazeli, S. A., Hashemi, S. M., Arabpour-Dahouei, F., Davarian, A., & Golabchifard, R. (2015) · Cited by 8
Kim, K. W., Kwon, H., Kim, S., Oh, S. Y., Lee, S., Lee, J. H., Roh, M. H., Kim, M. C., Kim, K. H., KIM, Y. H., et al. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.166 · Cited by 7
Pharmacogenomics and Personalized Medicine
Li, J., Bluth, M. H., & Ferreira‐Gonzalez, A. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0974-2.00072-5 · Cited by 7
Thymidine Phosphorylase: The Unforeseen Driver in Colorectal Cancer Treatment?
Tampellini, M., Bironzo, P., Maïo, M. D., & Scagliotti, G. V. (2018) · Future Oncology · doi:10.2217/fon-2017-0627 · Cited by 7
Prognostic value of biomarkers in metastatic colorectal cancer patients
Kataoka, K., Kanazawa, A., Nakajima, A., Yamaguchi, A., & Arimoto, A. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.10.006 · Cited by 6
Sarac, S. B., Rasmussen, C. H., Afzal, S., Thirstrup, S., Jensen, S. A., Colding‐Jørgensen, M., Poulsen, H. E., & Mosekilde, E. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2012.00885.x · Cited by 7
Schwarzenbach, H. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0022-5 · Cited by 6
Einama, T., Uchida, K., TANIGUCHI, M., Ota, Y., Watanabe, K., Imai, K., Karasaki, H., CHIBA, A., Oikawa, K., Miyokawa, N., et al. (2014) · Oncology Letters · doi:10.3892/ol.2014.2565 · Cited by 5
Wei, B., Wang, J., Zhang, X., Qian, Z., Wu, J., Sun, Y., Han, Q. Y., Wan, L., Zhu, J., Gao, Y., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.7069 · Cited by 5
Onwe, E. E., Ghani, F. A., Abdullah, M., Osman, M. B., Zin, R. R. M., Vivian, A. N., & Mohtarrudin, N. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_521 · Cited by 5
Molecular markers in colorectal cancer: clinical relevance in stage II colon cancer
Santos, C., Vilar, E., Capellá, G., & Salazar, R. (2013) · Colorectal Cancer · doi:10.2217/crc.13.24 · Cited by 4
Novel ProTide prodrugs of 5-fluoro-2′-deoxyuridine for the treatment of liver cancer
Jiang, L., Pan, T. S., Lv, Q., Yuan, W., Liu, X., Qu, X., Luo, D., Wan, S., & Cui, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115763 · Cited by 3
Metadata
- Authors
- Soong, R., Shah, N., Salto-Tellez, M., Tai, B. C., Soo, R. A., Han, H. C., Ng, S. S., Tan, W. L., Zeps, N., Joseph, D., Diasio, R. B., & Iacopetta, B.
- Affiliations
- National University of Singapore (SG)
- National University Hospital (SG)
- The University of Western Australia (AU)
- University of Alabama at Birmingham (US)
- Corresponding author
- Soong, R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 19
- Issue
- 5
- Pages
- 915-919
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC2931808
- OpenAlex
- W2108707912
- Cited by
- 136
- References
- 36
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 6 · 2018: 5 · 2017: 4 · 2016: 3 · 2015: 7 · 2014: 11 · 2013: 12 · 2012: 10
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4239 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- National University of Singapore (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- National Cancer Institute (R01CA116964, CA85381, R01CA085381)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, colorectal cancer, 5-fluorouracil, prognostic factors, chemotherapy response, survival
- MeSH terms
- Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Proteins, Neoplasm Staging, Prognosis, Thymidine Phosphorylase, Thymidylate Synthase, Colorectal Neoplasms, Survival Analysis, Chemotherapy, Adjuvant, Drug Resistance, Neoplasm, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.